PéptidosRD.COM

Single Peptides · Exact presentation

GHRP-6 · 2 mg Vial

GHRP-6 · 2 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.

Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.

Dosing & Reconstitution Guide

For a 2 mg presentation, the reference concentration of 0.67 mg/mL mathematically corresponds to 2.985 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 0.67 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0067 mg at this concentration.

Standard / Gradual Approach (3 mL = ~0.67 mg/mL)

The source chart summarizes “100 mcg–300 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Standard / Gradual Approach (3 mL = ~0.67 mg/mL)

Week/PhaseDose per Injection (mcg)Units (per injection) (mL)
Weeks 1–2100 mcg15 units (0.15 mL)
Weeks 3–4200 mcg30 units (0.30 mL)
Weeks 5–12300 mcg45 units (0.45 mL)

Reconstitution Steps

For a 2 mg presentation, the reference concentration of 0.67 mg/mL mathematically corresponds to 2.985 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 0.67 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0067 mg at this concentration.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]

Allow vials to reach room temperature before opening to reduce condensation uptake.

How This Works

It relates to the growth-hormone-releasing hormone, secretagogue receptor, and GH/IGF-1 axis. Each molecule acts at a different point and should not be treated as interchangeable.

Potential Benefits & Side Effects

GH/IGF-1 signaling is systemic and may carry metabolic, endocrine, and proliferative risks. No clinical regimen is provided here.

Potential Benefits:

Evidence ranges from medicines authorized for limited indications to experimental secretagogues with sparse human data. Evidence for the ingredient, formulation, and use must be separated.

Source trail

Scientific references and source discovery

How PeptidosRD selects, separates, and reviews sources